Overview
I am a Lecturer and cancer biologist in the Centre for Medical Education (C4ME) at Cardiff University. I teach physiology in Phase 1 of the MBBCh programme and facilitate case-centred team-based learning (cTBL) sessions for first- and second-year medical students.
Before joining C4ME, I was a postdoctoral researcher in the Division of Cancer and Genetics. My research focused on the STRIPAK signalling complex and intracellular cholesterol trafficking in cancer, examining their links to autophagy, cellular ageing and treatment responses.
As a Fellow of the Higher Education Academy (FHEA), I am committed to helping students connect biomedical science with clinical practice and fostering collaborations across teaching and research.
Publication
2026
- Li, A. X. et al. 2026. Targeting the MLN64/STARD3-cholesterol axis disrupts tight junction remodelling and attenuates gastric cancer aggressiveness. Frontiers in Oncology 16 1913732. (10.3389/fonc.2026.1913732)
- Chen, D. Y. et al., 2026. SRS387 - MLN64/StarD3 and StarD3NL in pancreatic cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.343. (10.1093/bjs/znag018.343)
- Li, A. X. et al. 2026. SRS126 - MLN64 and StarD3NL highly correlated with the autophagy marker SQSTM1 and BECN1 in breast cancer, and indicate prognostic and therapeutic potential [Abstract]. British Journal of Surgery 113 (S2) znag018.122. (10.1093/bjs/znag018.122)
- McKenna, M. et al. 2026. SRS85 Patey Prize Entrant - hENT1 inhibition as a strategy to overcome fluoropyrimidine resistance in colorectal cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.005. (10.1093/bjs/znag018.005)
- O’Neill, N. et al. 2026. SRS359 - A novel association between disialoganglioside (GD2), GD2 synthesising enzymes and the Angiomotin family in breast cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.318. (10.1093/bjs/znag018.318)
- Xiang, H. et al. 2026. SRS133 - Nucleolin (NCL) in clinical breast cancer, the prognostic and therapeutic implications [Abstract]. British Journal of Surgery 113 (S2) znag018.129. (10.1093/bjs/znag018.129)
- Cong, B. et al., 2026. MLN51 (Metastatic Lymph Node Gene 51)/CASC3 (Cancer Susceptibility Candidate Gene 3), A putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (2026), pp.1-17. (10.2147/BCTT.S565199)
- Cong, B. et al., 2026. MLN51 (metastatic lymph node gene 51)/CASC3 (cancer susceptibility candidate gene 3), a putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (10.2147/bctt.s565199)
2025
- Li, X. 2025. Molecular targeting striatins (STRNs) in connection with the Stripak complex in human solid cancers. PhD Thesis , Cardiff University.
2024
- Li, A. X. et al. 2024. Metastatic Lymph Node 64 (MLN64) expression in gastric cancer, the clinical and molecular implications in drug resistance. Cancer Genomics & Proteomics 21 (1), pp.30-40. (10.21873/cgp.20427)
2023
- Zhuang, X. et al., 2023. Expression of Claudin-9 (CLDN9) in breast cancer, the clinical significance in connection with its subcoat anchorage proteins ZO-1 and ZO-3 and impact on drug resistance. Biomedicines 11 (12) 3136. (10.3390/biomedicines11123136)
- Li, A. X. et al. 2023. Striatins and the STRIPAK complex partners in the clinical outcome of patients with breast cancer and responses to drug treatment. Chinese Journal of Cancer Research 35 , pp.365-385. (10.21147/j.issn.1000-9604.2023.04.04)
Articles
- Li, A. X. et al. 2026. Targeting the MLN64/STARD3-cholesterol axis disrupts tight junction remodelling and attenuates gastric cancer aggressiveness. Frontiers in Oncology 16 1913732. (10.3389/fonc.2026.1913732)
- Chen, D. Y. et al., 2026. SRS387 - MLN64/StarD3 and StarD3NL in pancreatic cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.343. (10.1093/bjs/znag018.343)
- Li, A. X. et al. 2026. SRS126 - MLN64 and StarD3NL highly correlated with the autophagy marker SQSTM1 and BECN1 in breast cancer, and indicate prognostic and therapeutic potential [Abstract]. British Journal of Surgery 113 (S2) znag018.122. (10.1093/bjs/znag018.122)
- McKenna, M. et al. 2026. SRS85 Patey Prize Entrant - hENT1 inhibition as a strategy to overcome fluoropyrimidine resistance in colorectal cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.005. (10.1093/bjs/znag018.005)
- O’Neill, N. et al. 2026. SRS359 - A novel association between disialoganglioside (GD2), GD2 synthesising enzymes and the Angiomotin family in breast cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.318. (10.1093/bjs/znag018.318)
- Xiang, H. et al. 2026. SRS133 - Nucleolin (NCL) in clinical breast cancer, the prognostic and therapeutic implications [Abstract]. British Journal of Surgery 113 (S2) znag018.129. (10.1093/bjs/znag018.129)
- Cong, B. et al., 2026. MLN51 (Metastatic Lymph Node Gene 51)/CASC3 (Cancer Susceptibility Candidate Gene 3), A putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (2026), pp.1-17. (10.2147/BCTT.S565199)
- Cong, B. et al., 2026. MLN51 (metastatic lymph node gene 51)/CASC3 (cancer susceptibility candidate gene 3), a putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (10.2147/bctt.s565199)
- Li, A. X. et al. 2024. Metastatic Lymph Node 64 (MLN64) expression in gastric cancer, the clinical and molecular implications in drug resistance. Cancer Genomics & Proteomics 21 (1), pp.30-40. (10.21873/cgp.20427)
- Zhuang, X. et al., 2023. Expression of Claudin-9 (CLDN9) in breast cancer, the clinical significance in connection with its subcoat anchorage proteins ZO-1 and ZO-3 and impact on drug resistance. Biomedicines 11 (12) 3136. (10.3390/biomedicines11123136)
- Li, A. X. et al. 2023. Striatins and the STRIPAK complex partners in the clinical outcome of patients with breast cancer and responses to drug treatment. Chinese Journal of Cancer Research 35 , pp.365-385. (10.21147/j.issn.1000-9604.2023.04.04)
Thesis
- Li, X. 2025. Molecular targeting striatins (STRNs) in connection with the Stripak complex in human solid cancers. PhD Thesis , Cardiff University.
Biography
Education and qualifications
- 2022: BSc in Physiology, University of Bristol, School of Life Sciences
- 2025: PhD, Cardiff University, School of Medicine
Career overview
- 2025–2026: CK Lau-funded Postdoctoral Researcher, Cardiff University, School of Medicine
- 2026–present: Lecturer in Biomedical Sciences, Centre for Medical Education (C4ME), Cardiff University
Honours and awards
- Fellow of the Higher Education Academy (FHEA) – awarded November 2026
- Associate Fellow of the Higher Education Academy (AFHEA) – awarded November 2025
- CK Lau foundation funded post-doctoral position 2025
- Finalist for PGR Student Excellent Impact & Innovation award 2025
- Taith - China-MEDIC Research Mobility Fund 2025
- HCARE & MEDIC Research Culture Fund 2024
- Early Career Researcher Travel Fund: 2022-2023 Cardiff University Division of Cancer and Genetics
- William Morgan Thomas Fund: 2022-2023
- M E Williams Fund: 2022-2023
Professional memberships
- European Association for Cancer Research (EACR)
- British Society for Gene and Cell Therapy (BSGCT)
- Wales Cancer Research Centre (WCRC) Early and Mid-Career Researchers Network